Stocks Health care ZIVO
OTC · Health careZivo Bioscience, Inc. (ZIVO)
Zivo Bioscience, Inc. brought in $209K of revenue over the twelve months to September 30, 2025, up 164.5% from a year earlier. It posted a net loss of $8.5M. At September 30, 2025 it held $57.2K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 14, 2025.
Watch ZIVO in 60 secondsWhat Zivo Bioscience, Inc. does
Zivo Bioscience, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker ZIVO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2024 | $157.2K | -$13.4M | -$4.23 | n/a |
| 2023 | $27.7K | -$7.8M | -$4.60 | n/a |
| 2022 | $0 | -$8.7M | n/a | n/a |
| 2021 | $0 | -$8.8M | n/a | n/a |
| 2020 | $20K | -$9.1M | -$0.02 | n/a |
| 2019 | $0 | -$11.5M | -$0.04 | n/a |
Full financial statements: income, balance sheet and cash flow
Where ZIVO ranks in Health care
Dividends
Zivo Bioscience, Inc. paid $3.11 per share in fiscal 2023.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2023 | $3.11 | n/a | n/a |
Latest SEC filings
What Zivo Bioscience, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- March 31, 2026Deregistration 15-12G
- March 31, 2026Form S-8 POS filing S-8 POS
- March 31, 2026Form POS AM filing POS AM
- March 30, 2026
- February 27, 2026Activist stake changed SCHEDULE 13D/A
- December 23, 2025
- November 14, 2025Quarterly report 10-Q · period to September 30, 2025Revenue rose 108% to $65.6K versus the same quarter last year; diluted EPS -$0.27 versus -$0.67.
- September 10, 2025
- August 18, 2025
- August 14, 2025Quarterly report 10-Q · period to June 30, 2025Revenue was $53.4K; diluted EPS -$0.43 versus -$2.78.
Insider trades
What the people running Zivo Bioscience, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| April 17, 2026 | Strome Mark E10% owner | Boughtindirect | 100,000 | $200K |
| February 27, 2026 | Yaldoo Laith LDirector, 10% owner | Boughtindirect | 1,543 | $15K |
| February 12, 2026 | Strome Mark E10% owner | Boughtindirect | 20,000 | $195.4K |
| February 10, 2026 | Yaldoo Laith LDirector, 10% owner | Boughtindirect | 2,434 | $25K |
| January 26, 2026 | Payne John BernardPresident and CEO, Director | Bought | 11,709 | $100K |
| January 26, 2026 | Cornell Alison ADirector | Bought | 11,709 | $100K |
| January 14, 2026 | Yaldoo Laith LDirector, 10% owner | Boughtindirect | 1,766 | $15K |
| January 14, 2026 | Maggiore Christopher D.Director, 10% owner | Bought | 1,766 | $15K |
| November 28, 2025 | Yaldoo Laith LDirector, 10% owner | Boughtindirect | 2,777 | $25K |
Who owns ZIVO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Mark E. Strome13D, may seek influence with 4 related filers | 12.1% | February 27, 2026 |
Largest institutional holders
Insiders
5 insiders reported holding 1,974,948 shares in total, about $6.5M at the last price.
| Holder | Shares |
|---|---|
| Yaldoo Laith LDirector, 10% owner | 583,615583,615 held indirectly |
| Strome Mark E10% owner | 572,942572,942 held indirectly |
| Maggiore Christopher D.Director, 10% owner | 519,292 |
| Cornell Alison ADirector | 279,481 |
| Payne John BernardPresident and CEO, Director | 19,618 |
Questions about ZIVO
What does Zivo Bioscience, Inc. do?
Zivo Bioscience, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker ZIVO.
Is Zivo Bioscience, Inc. profitable?
No. Over the twelve months to September 30, 2025 it reported a net loss of $8.5M on revenue of $209K.
How much revenue does Zivo Bioscience, Inc. make?
Over the twelve months to September 30, 2025 Zivo Bioscience, Inc. reported revenue of $209K. That is 164.5% more than a year earlier.
When did Zivo Bioscience, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 14, 2025. It covers the period to September 30, 2025. Its newest filing of any kind is the insider trade from April 24, 2026.
Similar companies
Compare ZIVO with
Follow ZIVO
Get an email when Zivo Bioscience, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ZIVO: get an email when it filesWhere the numbers come from
Financial figures are the values Zivo Bioscience, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.